GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » EV-to-EBITDA

Keymed Biosciences (HKSE:02162) EV-to-EBITDA : -28.50 (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Keymed Biosciences's enterprise value is HK$8,410.8 Mil. Keymed Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-295.1 Mil. Therefore, Keymed Biosciences's EV-to-EBITDA for today is -28.50.

The historical rank and industry rank for Keymed Biosciences's EV-to-EBITDA or its related term are showing as below:

HKSE:02162' s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.94   Med: -21.06   Max: 0.26
Current: -30.57

During the past 5 years, the highest EV-to-EBITDA of Keymed Biosciences was 0.26. The lowest was -57.94. And the median was -21.06.

HKSE:02162's EV-to-EBITDA is ranked worse than
100% of 455 companies
in the Biotechnology industry
Industry Median: 10.21 vs HKSE:02162: -30.57

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), Keymed Biosciences's stock price is HK$39.40. Keymed Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.498. Therefore, Keymed Biosciences's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Keymed Biosciences EV-to-EBITDA Historical Data

The historical data trend for Keymed Biosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences EV-to-EBITDA Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - -1.13 -37.08 -37.50

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only -1.13 - -37.08 - -37.50

Competitive Comparison of Keymed Biosciences's EV-to-EBITDA

For the Biotechnology subindustry, Keymed Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keymed Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keymed Biosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Keymed Biosciences's EV-to-EBITDA falls into.



Keymed Biosciences EV-to-EBITDA Calculation

Keymed Biosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8410.796/-295.067
=-28.50

Keymed Biosciences's current Enterprise Value is HK$8,410.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Keymed Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-295.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Keymed Biosciences  (HKSE:02162) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Keymed Biosciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=39.40/-1.498
=At Loss

Keymed Biosciences's share price for today is HK$39.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Keymed Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.498.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Keymed Biosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Keymed Biosciences (HKSE:02162) Business Description

Traded in Other Exchanges
Address
No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.

Keymed Biosciences (HKSE:02162) Headlines

No Headlines